Makindo Medical Notes"One small step for man, one large step for Makindo" |
|
---|---|
Download all this content in the Apps now Android App and Apple iPhone/Pad App | |
MEDICAL DISCLAIMER: The contents are under continuing development and improvements and despite all efforts may contain errors of omission or fact. This is not to be used for the assessment, diagnosis, or management of patients. It should not be regarded as medical advice by healthcare workers or laypeople. It is for educational purposes only. Please adhere to your local protocols. Use the BNF for drug information. If you are unwell please seek urgent healthcare advice. If you do not accept this then please do not use the website. Makindo Ltd. |
Feature | Hodgkin Lymphoma | Non-Hodgkin Lymphoma |
---|---|---|
Cell of Origin | B lymphocytes, specifically characterized by the presence of Reed-Sternberg cells, which are large, abnormal B cells. | Can originate from either B lymphocytes (B-cell lymphomas) or T lymphocytes (T-cell lymphomas). Reed-Sternberg cells are absent. |
Age Group | Bimodal age distribution, most commonly affects young adults (ages 15-35) and older adults (over 55 years). | Can occur at any age, but incidence increases with age, especially common in older adults. |
Symptoms |
|
|
Spread Pattern | Typically spreads in a predictable, contiguous manner from one group of lymph nodes to another. | Can spread in a non-contiguous, unpredictable pattern, often involving extranodal sites such as the gastrointestinal tract, skin, or bone marrow. |
Subtypes | Primarily Classical Hodgkin Lymphoma (CHL) with subtypes: Nodular Sclerosis, Mixed Cellularity, Lymphocyte-Rich, Lymphocyte-Depleted. | Many subtypes classified as B-cell or T-cell lymphomas. Common B-cell subtypes include Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma, and Burkitt Lymphoma. |
Prognosis | Generally good with a high cure rate, especially when diagnosed early. The 5-year survival rate is high. | Varies widely depending on the subtype, stage at diagnosis, and patient factors. Indolent lymphomas may have a chronic course, while aggressive lymphomas can be curable with intensive treatment. |
Treatment |
|
|